Disclosure Document for a FDAMA Waiver

First Page		Document Content
Date: 2007-03-28 09:23:41 Clinical research Organochlorides COX-2 inhibitors Etoricoxib Pyridines Merck & Co. Cyclooxygenase New Drug Application Food and Drug Administration Pharmaceutical sciences Non-steroidal anti-inflammatory drugs Pharmacology		Disclosure Document for a FDAMA Waiver Add to Reading List Source URL: www.fda.gov Download Document from Source Website File Size: 11,20 KB Share Document on Facebook

	DEVELOPMENT OF PHARMACEUTICAL PRODUCTS UTILIZING EXTRUSION TECHNOLOGIES Graciela Terife Senior Scientist, Product Value Enhancement Merck & Co., Summit, NJ DocID: 1nXt9 - View Document
	Title: font: times; size: 18 point; style: plain; justified: center; capitalization: first word and Names only THE CHALLENGE OF DEVELOPING AN MMRVVV COMBINATION VACCINE Alan R. Shaw, PhD DocID: 1gGkP - View Document
	Your contact News Release Gangolf Schrimpf DocID: 1aWSz - View Document
	TRUSOPT Ped data PAR DocID: 1aNXe - View Document
	CNODES: A Canadian Initiative Samy Suissa Lady Davis Institute, Jewish General Hospital McGill University Montreal, Canada DocID: 1aAtH - View Document